Saturday 17 October 2026
Export LBPS’s income statement to Excel — free account
4D pharma PLC Sponsored ADR
LBPS Healthcare Biotechnology
Revenue growth for five consecutive years.
Follow LBPS
| Older periods | Dec '20 | Feb '21 | Jun '21 | Dec '21 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(215.05%) | (154.94%) | (453.64%) | (155.83%) | |
| (103.16%) | (122.50%) | (337.92%) | (77.95%) | ||
ROIC |
(79.48%) | (157.32%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(271.46%) | (346.09%) | (368.00%) | (86.73%) | |
Average Days of Receivables |
0.00 | 0.00 | 3,415.75 | 2,646.62 | |
Free Cash Flow per Share |
(3.13) | 0.00 | 0.00 | (0.26) | |
Free Cash Flow |
(44.61) | (55.93) | (71.38) | (46.25) | |
Capital Expenditures |
— | (1.67) | (1.21) | — | |
| Other line items | |||||
Cash ROIC |
(85.69%) | (107.45%) | (83.24%) | (70.38%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.14 | 0.12 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Inventory Turnover |
0.00 | — | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
0.00 | — | 0.00 | 0.00 | |
Tax Rate |
(0.25) | 0.00 | (0.09) | (0.34) | |
Research and Development Expense of Revenue |
0.00% | — | 4,822.91% | 3,879.85% | |
Selling, General and Administrative Expense of Revenue |
0.00% | — | 1,285.44% | 1,414.74% | |
Share Based Compensation of Revenue |
— | 0.00% | 4,848.08% | 0.00% | |
Interest Coverage |
(39.47) | — | 0.00 | 0.00 | |
Operating CF/Net income |
0.94 | 0.90 | 0.51 | 1.63 | |
Depreciation/Fixed assets |
1.11 | 1.09 | 0.83 | 0.93 | |
Capex/Depreciation |
0.00 | (0.30) | (0.26) | 0.00 | |
Revenue per Share |
0.00 | — | 0.00 | 0.01 | |
Operating CF per Share |
(3.13) | 0.00 | 0.00 | (0.26) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | 0.94 | 0.00 |
Columns are period end dates · fundamentals updated 5 Oct 2026